These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 29450984)
1. Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations. Bai Q; Pérez-Sánchez H; Shi Z; Li L; Shi D; Liu H; Yao X Chem Biol Drug Des; 2018 Jul; 92(1):1221-1231. PubMed ID: 29450984 [TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Yin J; Mobarec JC; Kolb P; Rosenbaum DM Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960 [TBL] [Abstract][Full Text] [Related]
3. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA. Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076 [TBL] [Abstract][Full Text] [Related]
7. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. Karhu L; Turku A; Xhaard H BMC Struct Biol; 2015 May; 15():9. PubMed ID: 25957175 [TBL] [Abstract][Full Text] [Related]
8. Interaction between the Human OX2 Orexin Receptor and Suvorexant and Some of Its Analogues: SAPT (DFT) Interaction Energy Decomposition Analysis. Farrokhpour H; Bamdad F; Ashrafizaadeh M J Phys Chem B; 2022 Oct; 126(39):7528-7540. PubMed ID: 36166366 [TBL] [Abstract][Full Text] [Related]
10. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis. Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975 [TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480 [TBL] [Abstract][Full Text] [Related]
12. Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms. Borgatti DA; Rowlett JK; Berro LF Drug Alcohol Depend; 2024 Jun; 259():111285. PubMed ID: 38636173 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. Rappas M; Ali AAE; Bennett KA; Brown JD; Bucknell SJ; Congreve M; Cooke RM; Cseke G; de Graaf C; Doré AS; Errey JC; Jazayeri A; Marshall FH; Mason JS; Mould R; Patel JC; Tehan BG; Weir M; Christopher JA J Med Chem; 2020 Feb; 63(4):1528-1543. PubMed ID: 31860301 [TBL] [Abstract][Full Text] [Related]
15. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547 [TBL] [Abstract][Full Text] [Related]